A carregar...
Safety and Effectiveness of Ixazomib Dose-escalating Strategy in Ixazomib-Lenalidomide-Dexamethasone Treatment for Relapsed/Refractory Multiple Myeloma
Background/Aim: Gastrointestinal toxicity is common in patients receiving common therapy of ixazomib with lenalidomide and low-dose dexamethasone (IRd) for relapsed/refractory multiple myeloma. Here, we investigated the safety and effectiveness of ixazomib dosing schedules. Patients and Methods: We...
Na minha lista:
| Publicado no: | In Vivo |
|---|---|
| Main Authors: | , , , , , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
International Institute of Anticancer Research
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7652488/ https://ncbi.nlm.nih.gov/pubmed/32871820 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.21873/invivo.12108 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|